Suzhou Fushilai Pharmaceutical Co., Ltd. (SHE:301258)

Market Cap	3.33B
Revenue (ttm)	439.57M
Net Income (ttm)	75.96M
Shares Out	89.68M
EPS (ttm)	0.84
PE Ratio	44.11
Forward PE	n/a
Dividend	0.09 (0.24%)
Ex-Dividend Date	Jun 12, 2025

Volume	3,787,060
Average Volume	1,688,946
Open	36.84
Previous Close	36.91
Day's Range	36.47 - 38.31
52-Week Range	20.56 - 39.28
Beta	0.53
RSI	74.87
Earnings Date	Apr 23, 2026

About SHE:301258

Suzhou Fushilai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and health care raw materials in China and internationally. The company offers lipoic acid products comprising granular alpha lipoic acid, R-lipoic acid, r-lipoic acid tromethamine salt, and 6,8-dichlorooctanoic acid ethyl ester; l-carnosine; phosphatidylcholine products, which include glycerylphosphatidylcholine; and erelcoxib API, a nonst...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 524
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 301258

Financial Performance

In 2024, SHE:301258's revenue was 429.47 million, a decrease of -12.23% compared to the previous year's 489.29 million. Earnings were 16.41 million, a decrease of -85.38%.